ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Adeona Pharmaceuticals Common Stock

Adeona Pharmaceuticals Common Stock (AEN)

0,00
0,00
(0,00%)
Geschlossen 24 Januar 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
-
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

AEN Neueste Nachrichten

Adeona Becomes Synthetic Biologics, Inc.

Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New NYSE Amex Ticker Symbol: SYN -- PR Newswire ANN...

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN...

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- PR Newswire ANN...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed New...

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis PR Newswire ANN ARBOR, Mich., Jan. 19, 2012 ANN ARBOR, Mich., Jan. 19, 2012...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice Pr...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development -- Name Change Reflects Primary...

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator -- PNA Center for Neurological Research Clinical Study Results Presented at the 22nd International Symposium on...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary ...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension PR Newswire ANN ARBOR, Mich., and GERMANTOWN...

Adeona Reports Third Quarter 2011 Financial Results

Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- PR Newswire ANN ARBOR, Mich., Nov. 14, 2011 ANN ARBOR...

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research PR Newswire ANN ARBOR, Mich., Nov. 11, 2011 ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

AEN - Frequently Asked Questions (FAQ)

What is the current share price?
The current share price of is US$ 0,00
What is the 1 year trading range for share price?
has traded in the range of US$ 0,00 to US$ 0,00 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 24,265
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 25,48
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,635
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 27,22
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,205
(0,00%)
0
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 24,265
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 25,48
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,635
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 27,22
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,205
(0,00%)
0
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 24,265
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 25,48
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,635
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 27,22
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,205
(0,00%)
0
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock